Introduction
Captopril (SQ 14225), an orally active competitive inhibitor of angiotensin-I-converting enzyme, is an effective antihypertensive agent in patients with essential hypertension, renovascular hypertension, and hypertension associated with renal insufficiency.'-6 Its antihypertensive action has been attributed to blockade of the formation of the vasoconstrictor octapeptide angiotensin II.3 Additional mechanisms such as accumulation of bradykinin may play a part in the hypotensive effect, since the kinin-degrading enzyme kininase II is identical with angiotensinconverting enzyme. 7 To test captopril's specificity of action we examined the effect of a single oral dose in five anephric patients in whom plasma renin activities were extremely low.
Patients, methods, and results
Five patients (three women and two men, aged 29-53) had undergone bilateral nephrectomy from two to 11 years before the study and were undergoing long-term haemodialysis. The reasons for nephrectomy were: uncontrollable severe hypertension in four patients (three with essential hypertension, one with progressive systemic sclerosis) and intractable renal infection in one patient (adult polycystic disease). They were all studied as outpatients while adhering to a diet containing 100 mmol (mEq) sodium and 50 mmol (mEq) potassium daily. They had no oedema and showed no clinical or radiological evidence of congestive heart failure. None were receiving vasoactive drugs. The serum concentrations of sodium, potassium, and calcium were normal in all patients. The studies were performed 24 hours after each patient's regular haemodialysis.
Captopril $ PRA = Plasma renin activity (tsg angiotensin I/l/h).
Discussion
The blood-pressure lowering effect of captopril is associated with a decrease in total peripheral resistance. Captopril was recently reported to have lowered blood pressure in an anephric patient, 1 but to have failed to do so both when the patient was volume loaded and after he had lost 4-3 kg as a result of ultrafiltration dialysis. Mean arterial pressure rose slightly when captopril was given after dialysis (which we also observed in three of our patients). A third captopril test performed after he had lost a further 1 2 kg led to profound orthostatic hypotension. Although this may have been caused by captopril, nearly two hours elapsed between control pressure measurements and administration of captopril. Failure of physiological buffer mechanisms to maintain blood pressure during this period of intravascular volume depletion, rather than the action of captopril, may have been responsible for the augmented postural decline in blood pressure. In contrast, each patient in our study had a stable blood pressure in an upright, seated position for at least 30 minutes before receiving captopril.
The same authors have recently extended their studies.1 7 They observed reductions in blood pressure in seven anephric patients when captopril was given one hour after haemodialysis. Administering captopril 24 hours after dialysis, however, did not produce a hypotensive effect, which is consistent with our present findings. Thus the fall in blood pressure occurred only when captopril was given soon after dialysis, which suggests a mechanism related to the haemodialysis procedure. Exposure of blood to the haemodialysis membrane may have increased the production of vasodepressor kinins. If the hypotensive response was due to inhibition of kinin degradation by captopril then this response would be expected to be most evident soon after dialysis, as was observed.
Three of our patients showed an increase in mean arterial pressure after captopril. This increase ranged from 12% to 18'/ above the control pressure and reached a maximum 60 minutes after administration. A slight pressor effect after intravenous teprotide in some anephric patients has been observed.15
Neither the mechanism of this effect nor its importance in anephric patients or in patients with kidneys receiving captopril is known.
Recent reports have emphasised the increased incidence and intensity of exposure to hydrocarbon solvents in patients with chronic glomerulonephritis (in particular Goodpasture's syndrome and proliferative glomerulonephritis) compared with a control population with no renal disease.1-4 Rapidly progressive glomerulonephritis in rats exposed to petroleum vapours2 or fed N,N'-diacetylbenzidine5 showed that hydrocarbon-induced glomerulopathy does occur. A cause-and-effect relation between hydrocarbon exposure and human glomerulopathies based on statistical data has not been reported, however, except perhaps for the case described by Von Schiele et al. 4 All Von Scheele's patients have had chronically deteriorating disease.
Case report
A man aged 59 years was admitted with all the signs and symptoms of a nephrotic syndrome. At work he had been exposed for prolonged periods to hydrocarbon derivatives. The figure shows the changes in proteinuria, albuminaemia, oedema, and body weight in relation to successive periods of contact with hydrocarbons and rest periods over 27 months of follow-up. The creatinine clearance remained normal, and the patient received no treatment. Clinical and laboratory investigations showed a close correlation between a worsening of the nephropathy and exposure to toxic products at work and the complete reversal of disease activity after leaving that job. Renal biopsy, carried out with light, immunofluorescence, and electron microscopy, showed the features of a membranous glomerulonephritis. Electron microscopy indicated that adjacent to small, probably recent, deposits on the subepithelial layer of the glomerular basement membrane were many deposits embedded in the membrane, and it also showed electronlucent lacunae. 
